Cells were fixed with 4% paraformaldehyde (pH 7.4) for 30 min. The cells were then permeabilized with 0.2% Triton X-100, and non-specific binding sites were blocked with Block Ace (Yukijirushi). Cells were incubated with primary antibodies at 4°C overnight and with secondary antibodies at room temperature for 1 hr. Fluorescent images were captured using
IN Cell Analyzer 6000, and the percentage of MNs or neurons was calculated using
IN Cell Developer Toolbox v1.9 (GE Healthcare). For phenotype assays, images were acquired by
Delta Vision (GE Healthcare). The primary antibodies were as follows: HB9 (Developmental Studies Hybridoma Bank [DSHB], 1:200), Tuj1 (Covance, 1:2,000), Tuj1 (Chemicon, 1:500) for
Figures 6A and 6C, ChAT (Chemicon, 1:100), HOXB4 (DSHB, 1:50),
HOXC6 (Abcam, 1:200), HOXC9 (Abcam, 1:200),
HOXC10 (Abcam, 1:2,000), misfolded SOD1 (MEDIMABS, B8H10, 1:200), misfolded SOD1 (MEDIMABS, A5C3, 1:200),
TDP-43 (Proteintech, 1:200), human Nanog (ReproCELL, 1:500),
SSEA4 (Millipore, 1:200),
SSEA1 (Chemicon, 1:1,000),
Nestin (Millipore, 1:200),
GFAP (Dako, 1:2,000), Iba1 (Wako Pure Chemicals Industries, 1:500),
CNPase (Cell Signaling Technology, 1:100),
SOX17 (R&D Systems, 1:200), and
αSMA (Dako, 1:500). Tuj1 (Chemicon) was used to co-immunostain with
TDP-43.
Goto K., Imamura K., Komatsu K., Mitani K., Aiba K., Nakatsuji N., Inoue M., Kawata A., Yamashita H., Takahashi R, & Inoue H. (2017). Simple Derivation of Spinal Motor Neurons from ESCs/iPSCs Using Sendai Virus Vectors. Molecular Therapy. Methods & Clinical Development, 4, 115-125.